Developing Guidelines to Risk Stratify Patients that would Benefit from VTE Prophylaxis Úpon Discharge



Northeast Georgia Medical Center GRADUATE MEDICAL EDUCATION

Introduction

Venous thromboembolism (VTE) is the second leading cause of mortality in cancer patients. They are 4-7 times more likely than noncancer patients to develop VTE, and approximately 20% of all VTE are diagnosed in this patient population. (Streiff, Farge, Heit) The increased susceptibility of cancer patients to VTE is multifactorial, including but not limited to: age, race, sex, comorbidities, BMI, Virchow's Triad, hypercoagulable/pro-thrombotic state, and anticancer treatment. (Conner, Abdol) This patient population requires special attention for admission, pre-operative anticoagulation, as well as post-operative anticoagulation and management as they have a higher rate of VTE, as well as higher rates of VTE recurrence and bleeding complications than patients without cancer.

The topic of cancer associated thrombosis (CAT) is already complex, and when this population is undergoing major surgery, they are at a higher risk of VTE than the regular population. Guidelines from ASCO, ITAC, SEOM, and NCCN recommend pre-operative thromboprophylaxis and recommend that thromboprophylaxis be continued for 7-10 days at least, with both Caprini score and NCCN guidelines recommending thromboprophylaxis for 28-30 days in high risk patients undergoing major abdominal or pelvic surgery (Streiff). High risk patients include those with restricted mobility, obesity, history of VTE, surgery > 2 hours, malignancy, advanced stage cancer, bed rest >4 days, age >60 years, or additional risk factors. (NCCN).

Conclusion

To obtain the data for this study we reviewed medical records from 2020-2022 and included any cases that had DVT/PE on re-admission after previous new cancer diagnosis/surgery. We were unable to effectively capture all of the data we wished, as new cancer diagnoses that are not formally staged during a patient's hospitalization were not able to be captured in our data set. Despite multiple attempts are harvesting data different ways, we were only able to capture the data from patient's with formal cancer diagnoses entered into the system.

Of these cases reviewed, 67 patients with new cancer diagnoses had been re-admitted for DVT/PE, 50F and 17M. 37 of these patients were colorectal patients, 30 of these patients were gynecological oncology patients, 6 were TACS patients, and two other miscellaneous patients. Two were discharged home on anticoagulation, 28 were undergoing chemotherapy at the time of DVT/PE.

This small patient population was not useful for any statistical analysis. We would encourage the use of a BPA to decrease these numbers in the future as there is clearly an opportunity for improvement. This study lends itself to further investigation once the BPA is instituted and now that more oncologic surgeries are being performed with the addition of a hepatobiliary surgery service at NGHS.

BPA

Comprehensive NCCN Cancer Network®

• NCCN Guidelines Version 2.2023 **Cancer-Associated Venous Thromboembolic Disease**

VTE PROPHYLAXIS OPTIONS: AMBULATORY MEDICAL ONCOLOGY PATIENTS AND PATIENTS POST-MEDICAL ONCOLOGY DISCHARGE (VTE-2

Agent	Standard Dosing	Renal Dose	Other Dose Modifications
Apixaban ^{i,19}	2.5 mg PO twice daily	Avoid if CrCl <30 mL/min	Avoid if platelet count <50,000/µL Avoid if weight <40 kg
Rivaroxaban ^{j,20}	10 mg PO once daily	Avoid if CrCl <30 mL/min	Avoid if platelet count <50,000/µL
Dalteparin ^{k,21}	200 units/kg SC daily x 1 month, then 150 units/kg SC daily x 2 months	Avoid if CrCl <30 mL/min	Avoid if platelet count <50,000/μL
Enoxaparin ^{k,22}	1 mg/kg SC daily x 3 months, then 40 mg SC daily	Avoid if CrCl <30 mL/min	Avoid if platelet count <50,000/µL

Table 1.	Caprini Risk Asses	ssment Model			
1 Point		2 Points	3 Points	5 Points	
Age 41-60 y		Age 61-74 y	Age ≥ 75 y	Stroke (< 1 mo)	
BMI > 25		Arthroscopic surgery	History of VTE E	Elective arthroplasty	
History of major surgery (< 1 mo)) Major open surgery ≥ 45 min	Family history of VTE	Hip, pelvis, or leg fracture	
Varicose veins		Laparoscopic surgery > 45 min	Positive Factor V Leiden	Multiple trauma (< 1 mo)	
Swollen legs		Cancer (past or present)	Positive prothrombin 20210A	Acute spinal cord injury (< 1 mo)	
Acute MI		Patient confined to bed (> 72 h)	Elevated serum homocysteine		
CHF (< 1 mo)		Immobilizing plaster cast (< 1 mo)	Positive lupus anticoagulant		
Sepsis (< 1 mo)		Central venous access	Elevated anti-cardiolipin antibodies		
Serious lung disease			Heparin-induced thrombocytopenia		
COPD			Other congenital or acquired thrombophilia		
Bed rest					
Caprini score	Risk category	Recommend	ed prophylaxis	Recommended duration of chemoprophylaxis	
)	Lowest	Early frequent ambulation only, OR at discretion of surgical team: mpression boots OR low dose heparin OR low molecular weight heparin		During hospitalization	
1-2	Low	Compression boots OR low dose heparin OR low molecular weight heparin (choose 1 item)		During hospitalization	
3-4	Moderate	Compression boots AND low dose heparin OR low molecular weight heparin (choose 1 medication)		During hospitalization	
5-8	High	Compression boots AND low dose heparin OR low molecular weight heparin (choose 1 medication)		7–10 days total	
≥9	Highest	Compression boots AND low dose heparin OR low molecular weight heparin (choose 1 medication)		30 days total	

Study Objective

By using a combination of scoring systems to assist in risk stratification, the goal is to provide appropriate pre-operative and post-operative prophylaxis in high risk populations by utilizing an inclusive Best Practice Advisory (BPA). This BPA would include three different recommendations to include a variety of patients. The Khorana risk score (KRS), a validated risk stratification tool that can identify ambulatory patients with cancer receiving chemotherapy who are at increased risk for VTE (Khorana). The Caprini score, a validated scoring system to identify patient's who are high risk for DVT after surgery (Caprini, Gould). As well as the NCCN guidelines, for patients newly diagnosed with cancer. Based on these data, the option of thromboprophylaxis for ambulatory, at-risk patients, with and with-out cancer can be standardized for improved utilization and improved patient outcomes.


NCCN Guidelines Index Table of Contents Discussior

<mark>2)</mark> g,h

		Khorana score		
Risk	factor	Points		
Site of primary tur	nor			
Very high risk (stomach, pancreas)		2		
High risk (lung, lymphoma, gynecologic, bladder, testicular)		1		
All other sites		0		
Pre-chemotherapy platelet count ≥350,000/microL		1		
Hemoglobin level <10 g/dL or use of ESAs		1		
Pre-chemotherapy WBC >11,000/microL		1		
BMI ≥35 kg/m ²		1		
	Incidence o	of VTE based on Kl	norana score	
Khorana score points	Derivation cohort ^[1]	Validation cohort ^[1]	Independent cohort ^[2]	Patients in phase I trials ^[3]
	VTE risk after 2.5 months	VTE risk after 2.5 months	VTE risk after 6 months	VTE risk after 2 months
0 (low)	0.8%	0.3%	1.5%	1.5%
1 to 2 (intermediate)	1.8%	2%	3.8% (1 point); 9.6% (2 points)	4.8%
≥3 (high)	7.1%	6.7%	17.7%	12.9%

2020; 38:496 August 29, 2020 August 29, 2020. PMID: 1754886.

Leigh Peck Morgan Krause Emily Murdoch



References

1. Lip GY. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. AM J Med 2011; 124:111

2. Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, et al. NCCN guidelines insights: Cancer-associated venous thromboembolic disease, version 2.2018. J Natl Compr Cancer Netw. 2018;16(11):1289–303.

3. Streiff MB et al. Update on Guidelines for the Management of Cancer-Associated Thrombosis. The Oncologist. 2020;26(1)e24-e40. https://doi.org/10.1002/onco.13596 4. Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566–81.

5. Connors JM. Prophylaxis against venous thromboembolism in patients with cancer. N Engl J Med 2014;371:1263–1264

6. Key NS, Khorana AA, Kuderer NM et al. Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol

7. Khorana AA, Francis CW, Culakova E, et al Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5:632 8. Khorana AA, Soff GA, Kakkar AK et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019;380:720–728.

9. Klok, FA, Hösel V, Clemens A, et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J 2016; 48:1369. 10. Xiong, W. Current status of treatment of cancer-associated venous

thromboembolism. *Thrombosis J* **19**, 21 (2021).

11. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997;84:1099–1103. 12. Key NS, Khorana AA, Kuderer NM et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020;38:496–520.

13. Bergqvist D, Agnelli G, Cohen AT et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975–980. 14. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: A multicenter randomized open-label study. J Thromb Haemost 2006;4:2384–2390.

15. Farge D, Frere C, Connors JM et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2019;20:e566-e581.

16. NCCN Guideline on Cancer-Associated Venous Thromboembolic Disease. Version 1. 2020. Available at <u>https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf</u>. Accessed

17. Munoz Martin AJ, Gallardo Diaz E, Garcia Escobar I et al. SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019). Clin Transl Oncol 2020;22:171–186. 18. Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment. Cancers (Basel). 2018 Oct 11;10(10):380. doi: 10.3390/cancers10100380. PMID: 30314362; PMCID: PMC6209883. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209883/

19. Heit J et al. Arch Intern Med 162:1245-8, 2002. 2. Carrier M et al. Ann Intern Med 149:323-33, 2008. 3. Heit J et al. Arch Intern Med 160:809-15, 2000. 4. Khorana A et al. Cancer 104:2822-9, 2005. 5. Blom J et al. Jama 293:715-22, 2005.

20. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism: A Population-Based Case-Control Study. Arch Intern Med. 2000;160(6):809-815. doi:10.1001/archinte.160.6.809

21. NCCN Guideline on Cancer-Associated Venous Thromboembolic Disease. Version 1. 2020. Available at <u>https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf</u>. Accessed

22. Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991;17 Suppl 3:304-12.

23. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e227S-e277S. doi: 10.1378/chest.11-2297. Erratum in: Chest. 2012 May;141(5):1369. PMID: 22315263; PMCID: PMC3278061.

Nicole Redenius, DO Elaine Lelli, MD Michael Cormican, MD